Chris Marquette Message Board

Yeah, looks like it. If the synopsis wasn't maybe exaggerating a little... And it's not that I could tell if he's a good or bad player. Deb, you need to bring me up to speed when I'm over. And, look at this: You'll get to see the beefed up body in a baseball uniform, isn't that enough to look forward to?

-TeeJay

We got a love letter for Chris in Polish? Gee, I must have tagged it as spam and thrown it away unread. Bad me. Let me have a look, I think it's still on our server. You sure it wasn't spam?

Hm, okay, so this is the message:
I LOVE YOU!!!!!!!!!!!!!!!!!!!!to moj nr gg:9427885 and my sister number gg 3688209 !!!!!! speak my ! Adam w filmie a w zyciu misiu Chris kocham Cie !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

It does seem like it's something that relates to Chris and is not spam. Yeah, sure, like he's gonna call anyone giving him his number, even if it was his official site! Sheesh, how dumb are these people. We're not gonna reply to this one, are we?

-TeeJay

I don't believe this! I found more envelopes in that birthday box. And you wouldn't believe the amount of money that was in there. Man.... I totally forgot about all of that. Let's just say the sum has three digits and the first number is not a 1. :-O We really need to blow this on something. Deb, I'm gonna invite you big time when I come over. And Anne, the next we meet, I'm gonna invite you too. Maybe I should just buy you all the stuff you wanted me to bring from the US and you don't have to pay me back. Really, I really wanna share my lucky treasure finding with you two, seeing how I'm actually the one of us three to need it the least.

-TeeJay

Yep, that's the one, Anne.   Don't you just love it?

And you know what? I'm beginning to like cleaning up. Because..... I just found 50 EUR!!! I had this box with little birthday presents that my parents gave me for my 30th birthday (back in January, obviously) and there was a pair of socks with money inside in there. I knew there were coins in it, but I didn't realize my parents also put in 5 EUR bills in there. Amounted to 50 EUR. Wow! Deb, Anne, I think we need to blow this unexpected infusion of doe on something we can share. Any ideas?

-TeeJay

Okay, all fixed (I hope). Try to reload if it doesn't show up right away. Thanks for pointing these things out, Deb. The 2x8 instead of 2x08 was purely coincidental. Didn't mean to leave out the zero. I fixed that too, along with the Just Friends and the Shadows And Light thing.

-TeeJay

Okay, so here's some more Tina standing up and talking about addiction and drugs. Because I just found this article I copied a while ago because I thought it was interesting. If you get bored, here's some reading material for you. (If you find mistakes, that's not my fault but the fault of my OCR text recognition software.) Well, most of this is about drugs to help with addiction, but maybe you still find it interesting.

Eye On: Addiction

Addiction and substance abuse are increasing not only in frequency but in medical complications and direct and indirect costs. In the United States, 7.1% of the population used illicit drugs in 2001, up from 6.3% in 1999 and 2000. During the same time period, there were statistically significant increases in use of marijuana, cocaine, pain relievers and tranquilizers, and the prevalence of substance dependence or abuse increased from 14.5 million (6.5% of the population) to 16.6 million (7.3%). Drug use led to more than 600,000 emergency department visits in 2000, most often for alcohol in combination with other drugs (204,524), cocaine (174,896), heroin/morphine (97,287), and marijuana (96,446). In 1999, there were 19,102 deaths related to use of legal and illegal drugs.

In the workplace, medical and worker compensation claims for employed drug abusers are about double that for drug-free employees. Tobacco use alone is the single leading preventable cause of death in the United States, causing more than 440,000 deaths annually. The U.S. Centers for Disease Control and Prevention estimates that 49 million adults and 6 million teenagers smoke, causing $75.5 billion in excess medical costs and $81.9 billion in mortality-related productivity losses annually.

Recent advances in the science of addiction have shown that drugs interfere with normal brain function, creating short-term sensations of pleasure or euphoria, as well as long-term effects on brain metabolism and activity. These changes in the brain may herald the turning point from drug abuse to addiction, which is a chronic, relapsing illness requiring treatment typically including pharmacotherapy. Examples of currently available agents for treatment of addiction include methadone for heroin abuse, and the anti-depressant bupropion or nicotine replacement therapy via transdermal patches, chewing gum and/or inhalers for smoking cessation.

CenterWatch has identified a pipeline of 12 drugs in various stages of development for treatment of smoking, opiate, alcohol and marijuana addiction. Many of these agents target specific receptors at which the abused substance is active, whereas a few act as immune system modulators. Alkermes has submitted a new drug application (NDA) for Vivitrol (medisorb naltrexone). This narcotic antagonist is a sustained-release, injectable formulation of naltrexone using encapsulation in polymeric microspheres, allowing it to be given only once monthly. Indications may include alcoholism as well as opiate addiction. In a phase III, multicenter, double-blind clinical trial, 624 patients with alcoholism were randomized to receive either one of two doses of Vivitrol or placebo injected once monthly for six months, along with standardized, low-intensity counseling twice monthly. Compared with placebo, 380 mg of Vivitrol was associated with a 25% decrease in heavy drinking days. The drug was generally well-tolerated, with a discontinuation rate due to adverse events of 14.1%.

Another form of injectable, sustained-release naltrexone is Naltrel, in phase III testing by DrugAbuse Sciences for alcoholism and heroin addiction. Like Vivitrol, it uses microsphere technology based on polylac-tide polymers, and it is formulated for once monthly intramuscular injection. Slow release of naltrexone into the bloodstream allows it to trickle into the central nervous system (CNS), where it blocks endorphin receptors. Maintaining an effective concentration in the CNS for an entire month reduces noncompliance, which has previously been a major hindrance to effective addiction pharmacotherapy. Clinical trials to date have yielded convincing efficacy and safety data, with a statistically significant improvement over placebo in total abstinence and in cumulative days of abstinence. However, the primary efficacy variable of cumulative days of non-heavy drinking at three months showed no significant differences between Naltrel and placebo.

Pfizer has submitted an NDA for its anti-smoking drug varenicline (CP-526555), which is a partial agonist at the alpha-4 beta-2 nicotinic receptor. After seven weeks of treatment, about half of the several hundred smokers involved in clinical trials were able to quit smoking. An alternative approach to treating nicotine dependence is the glycine receptor antagonist GW 468816, in phase III development by GlaxoSmith-Kline. Yet another novel strategy to prevent and treat nicotine addiction is NicVAX, a vaccine against nicotine in phase II testing by Nabi Biopharmaceuticals. This vaccine triggers the immune system to produce antibodies binding to nicotine, thereby preventing it from entering the CNS. In this fashion, NicVax would prevent the positive stimulus in the brain normally associated with nicotine. In preclinical studies, NicVAX vaccination appears to block the effects of nicotine that can lead to addiction or that can reinforce and maintain addiction.

Other agents using nicotine-specific antibody-generating technology are CYT-002-NicQb (Nicotine-Qbeta), in phase I development by Cytos Biotechnology, and TA-NIC, in phase I testing by Xenova. In two phase I studies of TA-NIC, the dose groups with the highest levels of anti-nicotine antibodies had a clear increase in smoking cessation rates compared with the lowest dose and placebo groups.

A similar approach applied to a different addiction is Xenova's phase II product TA-CD (IPC-1010), a protein conjugate therapeutic vaccine that stimulates the production of antibodies against cocaine. It is administered by intramuscular injection, and it will probably require a short course of injections to induce antibody formation. In two clinical studies conducted to date, TA-CD vaccine was well tolerated both locally and systemically, with no severe or moderate adverse events. Anti-cocaine antibody levels rose proportionately with the dose of vaccine and with the number of vaccinations. Antibodies first appeared after the second injection, peaked about 12 weeks after the initial injection, and then decreased until one year.

In two dose-escalation phase II studies, the maximum mean antibody response to TA-CD occurred between 70 and 90 days following vaccination, and cocaine-specific antibodies persisted for at least six months. The probability of cocaine use decreased in subjects who received a more intense vaccination schedule and who produced higher levels of anti-cocaine antibodies. Even subjects who relapsed within six months reported a decrease in the euphoric effects of cocaine.

Sanofi-aventis is in phase III testing of rimonabant (Accomplia, SR 141716), a selective CB1 cannabinoid receptor antagonist targeting the brain's reward system. This drug was originally shown to be effective for weight loss or smoking cessation, but it also appears to show promise in treating drug addiction. In addition to blocking the effects of marijuana, it may help prevent relapses into alcohol and cocaine addiction. Lofexidine (BritLofex) is an alpha-2 adrenoceptor agonist, in phase III development by Britannia Pharmaceuticals and NIDA for treatment of opiate withdrawal symptoms in patients undergoing opiate detoxification. Lofexidine has been shown to be effective in reducing withdrawal symptoms including chills, sweating, stomach cramps, diarrhea, muscle pain, rhinor-rhea and watery eyes. Because it is not an opiate and does not cause addiction, it is not associated with any withdrawal symptoms of its own. However, it does not reduce cravings, and it is only helpful in overcoming the physical symptoms of opiate withdrawal.

Probuphine, in phase I testing by Titan Pharmaceuticals, is a six-month subcutaneous implant formulation of buprenor-phine designed for treatment of opiate addiction. Continuous long-term delivery of buprenorphine may reduce poor compliance, variable blood levels, risk of misuse, and other problems associated with daily oral therapy. The ProNeura drug delivery system, which is placed subcutaneously in the upper arm, consists of a small, solid rod made from a mixture of ethylene vinyl acetate (EVA) and buprenorphine, creating a solid matrix from which buprenorphine slowly diffuses.

In preclinical studies, Probuphine was able to deliver targeted therapeutic levels of buprenorphine for up to eight months without adverse effects. In an open label phase I/II clinical study, 12 opiate-dependent patients were successfully switched from daily sublingual buprenorphine to Probuphine without significant signs of withdrawal or craving, and without adverse effects.

For the treatment of methamphetamine addiction, Yaupon Therapeutics is in phase I development of lobeline, a nicotinic acetyl-choline agonist and dopamine modulator. Preclinical studies show that lobeline also protects dopamine-producing neurons, suggesting potential applicability to Parkinson's disease, and that it may improve learning, which could be useful in the treatment of attention deficit disorder. Greater understanding of the patho-physiology of reward centers in the brain and specific receptor types involved in mediating the effects of substances of abuse has spurred the development of new drugs targeting these pathways. Because recent evidence suggests that some brain changes associated with substance abuse may be irreversible, however, the long-term efficacy of these new agents may remain problematic.

—Laurie Barclay, M.D.

from: CenterWatch, April 2006

-TeeJay

No, he's more of a foolish kid with a death wish. This group of teenagers imitated those reality shows like MTV's Jackass, doing their own really dangerous and stupid stunts. Why they end up in the episode is because they though it would be a fun thrill, letting a spinning and firing machine gun drop down a bamboo stick in an abandoned storage hall somewhere. One of the kids was hit by a stray bullet in the chest and died. That's when the CSI guys come in and try to determine how he died.

But Eric is kinda cocky in the one scene where he speaks, mouthing off towards the cop who interviews him. And this is my turn to confess that for a while, when there was this kind of Jackass hype a few years back, I was really into the show. I think I've seen pretty much every episode of Jackass. It wasn't so much the fact that I wanted to be like them or thought they were cool. I always thought it was really stupid and some things really dangerous and pretty much all of them way foolish, but that had a kind of appeal to me that let me tune in to their show repeatedly. (I always liked Bam Margera best, the stupid little weirdo. But I wouldn't wanna be his parents.) When I watched it, I was always like: Geez, these crazy maniacs, WHY are they doing that to themselves???

I have not seen Jackass - The Movie, I have to add to my defense, though. But I think some day I just might. But I won't go as far as buying the DVD. And how did I end up talking about Johnny Knoxville and his manic set of friends in the Chris's Brothers thread?

-TeeJay

Anne wrote to me at work today, having this really weird (and slightly frightening) thought. We thought this movie was supposed to play in the 80's. Someone on IMDb said it was supposed to play in the 70's. If that's true, man, are we gonna see Chris in those awful bell-bottom 70's pants??? Dude, so not cool! But he's probably already sporting the kinda ugly Caesar cut, what more damage can those pants do?

But still, I think it would weird me out, seeing him in true 70's clothes. Maybe also one of those hideous shirts with the huuuuge collars and wild and big patterns. <shudders> Boy.... and we thought he'd look crappy in Alpha Dog. LOL So Fanboys is really gonna be some eye-candy, despite the face fuzz. Wonder what's to come next.

-TeeJay

Hm, yeah, the age thing could be a factor, I guess. I mean, his hair is short now, he may have had some face fuzz then. Yes, he would look totally different, even if they'd put him in a toque or something. It's still a shame, but I wasn't expecting much in terms of AG specials anyway. The JoA s2 specials are another matter, though. I hope to report some details soon.

Was Chris at least mentioned in the specials? Did Marcia say anything about him? I don't mind knowing.

You know what I just realized? We three all have different avatars from different things that Chris has done. Anne has AG (i.e. David), Deb has JF (i.e. Mike, or rather Chris himself here) and I have Huff (i.e. James). Nice.

-TeeJay

Here's another one in the category "posts that the world doesn't need":

Subject: hot
Text:
Chris Marquette is totallt hot!!! i'd do him anytime..anywhere.. i really love him

(i'm a sucker for nice ears like his and,lukas haas..)

chris:-

lukas:-

Ewww, that second guy is just ugly. And his ears are even uglier. Chris's ears are way nicer!!

And of course it's from IMDb, where else. Tell me, why do I keep going there??

Someone else posted the question of whether Chris doesn't remind you of Paul Dano. No. He doesn't. (Does he?) I find that quite absurd, seeing how they were in the same movie together.

-TeeJay

Sounds like Steph is getting a good share of Chris. You'll make her a Dorquette yet. Glad she liked everything so far. Yeah, he is a girly guy. He plays a girly sport, remember? We didn't pick badminton for no reason, right? And, yes, that's what we love about him. Deb, if I may quote you: There's nothing more sexy than a man who can cry shamelessly. The Dorquettes dig the tear ducts. Maybe that should become our motto. You know, besides [...]NEEDSAHUG!

Thank you for the praise on the Drool Towel. Yeah, I'm pretty proud of them too. They turned out very nice. I can't wait to get the other Dorquette shirts done. Those should be fairly easy, now I just need to find the time to make them. And I need your shirts, obviously.

Deb, I wrote to work today, because somehow I'm not sure if you told me you weren't working today and I forgot or if you didn't. But it was just one e-mail and I don't think there was anything in it that's not safe. Does someone else read your stuff when you're away? Are you back at work tomorrow?

-TeeJay

You're not expecting us to not use any abbreviations anymore, right? Actually, CGI is a fairly common abbreviation, even in German. If there's anything you don't know, just ask. I'll gladly explain anything you might not know.

And I'm going to Anja's place next weekend, maybe I'll just snag a copy of her Episode I DVD (shhhh!). I have Ep. II and III already. Eps IV to VI I only have on video.

-TeeJay